Brief: MaaT Pharma: Positive Interim Engraftment Data For Oral Formulation MaaT033

Maat Pharma SA

24/01/2022 06:52

Jan 24 (Reuters) - Maat Pharma SA  MAAT.PA :
    * POSITIVE INTERIM ENGRAFTMENT DATA FOR ORAL FORMULATION
MAAT033
ALLOWING EARLY TERMINATION OF PHASE 1B CIMON STUDY
    * MAAT033 IS A HIGH-RICHNESS, HIGH-DIVERSITY, DONOR-DERIVED
MICROBIOME ECOSYSTEM THERAPY FOR ORAL ADMINISTRATION
    * FOUR COHORTS HAVE COMPLETED STUDY IN DOSE-RANGING PHASE 1B
CIMON
TRIAL WITH MAAT033 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
    * PROOF-OF-ENGRAFTMENT: MAAT033 ACHIEVES A GOOD MICROBIOME
ENGRAFTMENT AND ENGRAFTMENT PERSISTENCE, TOGETHER WITH A
SATISFACTORY SAFETY PROFILE
    * COMPLETE RESULTS FOR TRIAL ARE EXPECTED IN FIRST HALF OF
2022,
AND ARE EXPECTED TO SUPPORT INITIATION OF A PHASE 2/3 TRIAL
PLANNED IN SECOND HALF OF 2022

Source text for Eikon:  ID:nBw75PrDta 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))